Moradpour D, Blum H E
Abteilung Innere Medizin II, Medizinische Universitätsklinik Freiburg i. Br.
Praxis (Bern 1994). 2002 May 29;91(22):977-82. doi: 10.1024/0369-8394.91.22.977.
Hepatitis C virus (HCV) infection is a leading cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma worldwide. Here, we will briefly review current and evolving therapies for chronic hepatitis C. Standard therapy with (pegylated) interferon-alpha and ribavirin achieves sustained response rates of up to about 40% in genotype 1- and about 80% in genotype 2- and 3-infected patients. Recent progress in the molecular virology and pathogenesis of hepatitis C has allowed the identification of novel antiviral targets and therapeutic strategies. These will likely complement existing therapeutic modalities in the near future.
丙型肝炎病毒（HCV）感染是全球范围内导致慢性肝炎、肝硬化和肝细胞癌的主要原因。在此，我们将简要回顾慢性丙型肝炎的现有及不断发展的治疗方法。使用（聚乙二醇化）α干扰素和利巴韦林的标准疗法在1型基因型感染患者中的持续应答率高达约40%，在2型和3型基因型感染患者中约为80%。丙型肝炎分子病毒学和发病机制方面的最新进展使得新型抗病毒靶点和治疗策略得以确定。在不久的将来，这些很可能会补充现有的治疗方式。
